Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 9,353

Document Document Title
WO/2023/064349A1
Pyrrolo[2,3-b]pyridine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,3-b]pyridine compound or analogs thereof, in the treatment of disorders ...  
WO/2023/064218A1
Compounds having activity as inhibitors of TYRO3 are provided. The compounds have Structure (I): (I) or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof, wherein L, X, Y, Z, R1, R2a, R2c, R3, p, and n are as...  
WO/2023/061432A1
A pyrimidine tricyclic derivative and a pharmaceutical application thereof. Specifically disclosed are a compound as represented by formula (I), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.  
WO/2023/061294A1
Disclosed are a nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and an application thereof. Particularly, disclosed are a compound as represented in general formula (I), a preparation method therefor,...  
WO/2023/064366A1
Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatme...  
WO/2023/064361A1
7H-Pyrrolo[2,3-d]pyrimidine compounds of Formula (I) for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 7H-pyrrolo[2,3-d]pyrimidine compounds or analogs thereof, in ...  
WO/2023/064879A1
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.  
WO/2023/061434A1
The present invention provides a use of a compound represented by formula (A) or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating cancer mediated by EGFR, FGFR2, KIT, ALK and/or ROS1 mutations. The comp...  
WO/2023/064880A1
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.  
WO/2023/061433A1
Provided is a compound of formula (A), N-(6-((5-bromo-2-((6-isopropyl-8-methoxy-3-methyl-3,4,5,6-te trahydrobenzo[b]pyrazolo[4,3-D]aza-9-yl)amino)-pyrimidin-4-y l)amino)-quinoxaline-5-yl)methanesulfonamide, and a compound of formula (I),...  
WO/2023/061463A1
A pyrimidopyridine compound, a pharmaceutical composition thereof, and a use thereof. Specifically, the present invention relates to a compound represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a met...  
WO/2023/059583A1
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...  
WO/2023/060253A1
The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.  
WO/2023/059605A1
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.  
WO/2023/059609A1
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from GSPT1, Cyclin K, RBM23, RBM39, IKZF1, IKZF3, PLK1, CDK4 or CKlalpha which is linked to a moiety that binds to a target protei...  
WO/2023/059581A1
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...  
WO/2023/056951A1
Disclosed is a novel substituted heterocyclic compound, which can be used as a K-RAS mutation target inhibitor. Specifically disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt, a solvate, a hydrate,...  
WO/2023/059582A1
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.  
WO/2023/056039A1
Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.  
WO/2023/051635A1
Disclosed in the present invention are a fused ring compound, and a preparation method therefor and the use thereof. Provided in the present invention are a fused ring compound as represented by formula I, a tautomer thereof, a stereoiso...  
WO/2023/053039A1
Provided herein are novel compounds having an inhibitory effect on the activation of a STING pathway. The provided compounds are 1,2-diaminobenzimidazole derivatives represented by a compound formula (I) or a pharmaceutically acceptable ...  
WO/2023/051648A1
Provided are a compound as an SHP2 inhibitor, a pharmaceutical composition thereof, and the use thereof in the prevention or treatment of SHP2 activity-mediated diseases.  
WO/2023/052312A1
The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including ...  
WO/2023/048573A1
The invention is directed to a hydrogenated Diels-Alder adduct according to formula (I) or a salt thereof wherein X is is H or an aliphatic moiety that is optionally substituted with one or more heteroatom-comprising substitutents such a...  
WO/2023/046182A1
Provided is an application of a pyrido[1,2-a]pyrimidone compound, and specifically involved is an application of a substance X in preparation of a drug. The substance X is a compound represented by formula I, a pharmaceutically acceptabl...  
WO/2023/049697A1
Claimed are compounds of Formula la, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or diso...  
WO/2023/041066A1
Provided are a pyrimidine-containing dihydropyrazolone derivative, a prodrug thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a preparation method therefor and an application thereof. The compound can i...  
WO/2023/040818A1
Disclosed are a RIPK1 inhibitor that inhibits programmed cell necrosis and a preparation method therefor. The disclosed RIK1 inhibitor is represented by general formula I, where X1, X2, X3, X4, X5, Z1, Z2, Z3, L1, L2, L3, R, R1, ring D a...  
WO/2023/042879A1
The present invention provides: a compound having coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. Provided is a compound represented by formula...  
WO/2023/040996A1
The present application relates to an azaindazole macrocyclic compound and the use thereof. The azainazole macrocyclic compound has a structure of formula I, and has the effect of inhibiting the activity of a plurality of protein kinases...  
WO/2023/042814A1
A compound represented by the general formula is useful as a light-emitting material. R1 to R10 represent a hydrogen atom, a deuterium atom or a substituent, provided that one or two of R1 to R10 represent a cyano group and one to four o...  
WO/2023/036175A1
Disclosed in the present invention are a glutarimide compound, and the use thereof. Specifically disclosed are a compound as represented by formula (VII-0) and a pharmaceutically acceptable salt thereof.  
WO/2023/039505A1
The present disclosure relates compounds of Formula (0): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, a...  
WO/2023/036156A1
The present application relates to a class of DNA-PK selective inhibitors as represented by formula (II), and a preparation method therefor and the use thereof. The use comprises the use of the compound of formula (II) in the preparation...  
WO/2023/036976A1
The present invention relates to a heterocyclic compound of formula (1), which is substituted by at least one cyano group, as well as compositions and devices comprising these compounds, especially organic electroluminescent devices comp...  
WO/2023/039089A1
The invention relates to a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, compositions comprising the same and methods of preparing and using the same.  
WO/2023/039464A1
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided...  
WO/2023/036993A1
The present invention relates to novel trityl-nitroxide radicals as polarizing agents for Dynamic Nuclear Polarization (DNP).  
WO/2023/034812A1
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.  
WO/2023/032940A1
The present invention provides a compound which has PDHK inhibitory activity and which is useful for treating or preventing diabetes (type 1 diabetes, type 2 diabetes, etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia...  
WO/2023/034811A1
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.  
WO/2023/032987A1
Provided are: a 6-aminopyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; and a pharmaceutical use thereof. A ...  
WO/2023/032676A1
A compound represented by formula (1). Formula (1): Z1-αa-βb-γc-δd-εe-Z2 [In formula (1), α, β, γ, δ, and ε are units respectively represented by formulae (1α), (1β), (1γ), (1δ), and (1ε), with the proviso that the unit α...  
WO/2023/029943A1
The present invention provides an aromatic heterocyclic compound, a preparation method therefor and an application thereof. The aromatic heterocyclic compound is shown in formula I. The aromatic heterocyclic compound provided in the pres...  
WO/2023/031399A1
The present invention concerns novel specific iron-activable nitrogen-containing derivatives of salinomycin and narasin, their synthesis and their uses in therapy notably for the treatment of cancer.  
WO/2023/034290A1
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...  
WO/2023/033018A1
The present invention provides a compound represented by formula (I). (In the formula, A1, A2, or A3 each independently is a carbon atom or a nitrogen atom, B1, B2, B3, or B4 each independently is a carbon atom or a nitrogen atom, X1 is ...  
WO/2023/034833A1
The present disclosure features compounds (I) and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.  
WO/2023/025290A1
A use of an SHP2 inhibitor for treating tumors containing RAS pathway gene mutations. Specifically, the present invention relates to the use of a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof in the prepa...  
WO/2023/025116A1
The present invention relates to a heterocyclic derivative, a preparation method therefor and the use thereof in medicine. Specifically, the present invention relates to a heterocyclic derivative represented by general formula (I), a pre...  

Matches 301 - 350 out of 9,353